BPC-157 Guide & Protocols

BPC-157 is one of the most talked-about peptides in this space, and the amount most people quote, 250 to 500 micrograms, gets repeated so often it sounds settled. It isn't, and where it actually comes from is more interesting than the number itself. Below is the pattern most commonly referenced, the sources behind it named honestly, how it's cycled and stacked, and how it compares to TB-500.

Vial size isn't part of what follows, since the amount of bacteriostatic water you add sets your concentration either way. Our reconstitution calculator handles that math for whatever vial and target dose you're working with.

What it is

BPC-157 is a synthetic pentadecapeptide, a chain of 15 amino acids, built from a partial sequence of a protective protein found in gastric juice. It doesn't occur naturally in this exact form; it was first isolated and studied by a research team at the University of Zagreb beginning in the early 1990s, led by researcher Predrag Sikirić. It's sometimes called PL 14736, PL-10, or simply "body protection compound," and it's a distinct class of compound from growth hormone secretagogues or steroid analogs. It's sold as a research chemical, not an FDA-approved drug or supplement, though it has been studied in human research for digestive conditions.

What people use it for

BPC-157 shows up in four overlapping conversations. Gut health and digestive comfort is where the research started, since the compound is drawn from a protective gut protein in the first place. Tendon, ligament, and muscle repair is the biggest conversation by volume, with a substantial amount of animal research behind it. Wound healing and skin repair comes up alongside it, and a smaller, more recent interest sits in joint and cartilage support, based mostly on a small human case series looking at knee pain rather than a larger body of evidence.

Formulations

BPC-157 ships as a lyophilized (freeze-dried) powder that needs reconstitution before use. Vendors most commonly sell 2, 5, and 10 mg vials. Unlike most research peptides, it's also sold in an oral form, usually an arginate salt formulated for gut-specific use, since the underlying compound is drawn from something the digestive tract already handles. Oral and injected amounts are not interchangeable, and sources that address both consistently treat them as separate protocols rather than the same dose taken a different way.

Dosing protocols

There's no single settled dose for BPC-157. What circulates is a handful of patterns from different kinds of sources, and they don't all agree, so here's each one with where it actually comes from.

See the BPC-157 research notes for more background before reading the dosing itself.

Injected, most commonly referenced pattern

250 to 500 mcg, once or twice daily, subcutaneous, for 4 to 8 weeks. This is the version repeated across the most vendor and telehealth education pages, usually described as reported in practice without a named clinician behind it.

Injected, a stricter variant

250 to 350 mcg twice daily, or 500 to 700 mcg once daily, for about 30 days. This version is commonly attributed to Ben Greenfield, a health author and podcaster rather than a physician, who treats the once-daily and twice-daily versions as interchangeable.

Injected, split by acute or chronic use

250 to 500 mcg twice daily for 2 to 4 weeks for an acute injury, or 200 to 300 mcg once daily for 4 to 12 weeks for something chronic. This split is commonly attributed to Jay Campbell, who publishes peptide protocols and traces his own numbers to a mix of community use, clinician observation, and animal-dose extrapolation.

Oral, for gut-specific use

500 to 1,000 mcg daily, oral, on an empty stomach, for 4 to 12 weeks. This pattern shows up in clinician and vendor literature aimed specifically at digestive use, using the arginate salt form for absorption. It's a separate protocol from the injected patterns above, not a different way of taking the same amount.

The one published human study of BPC-157 used a much smaller amount than any of the above: 0.4 micrograms daily, oral, for about a month, in research on ulcerative colitis, and the group getting the compound did better than the group getting a placebo. That's roughly 600 times smaller than the 250 microgram figure most commonly referenced (250 ÷ 0.4 = 625), which is worth sitting with. Some of that gap is explained by the study being oral rather than injected, but not most of it. Two standard ways of scaling an animal dose up to a person land in noticeably different places for someone around 165 pounds, one considerably lower and one considerably higher than 250 micrograms, and the popular number sits between them, while also happening to divide neatly into a 5 milligram vial.

One more thing worth naming: every pattern above was written for a body somewhere around 165 to 200 pounds, and none of the human-facing numbers adjust for size. A woman around 120 pounds running the standard flat amount is taking meaningfully more per pound of her than the figure was built around, which isn't something most sources mention.

Cycling guidelines

Four to six weeks on with an equal period off, or eight to twelve weeks on followed by a lighter maintenance schedule three to four times a week, are the two patterns most commonly described. We couldn't find a source for where either ratio came from, which makes it convention rather than a documented finding.

Signs a course is commonly stopped early:

• Persistent injection-site reaction beyond mild, brief redness
• New digestive symptoms that don't resolve within the course
• Any new symptom you can't otherwise explain

Stacking

Most popular stack: BPC-157 and TB-500, sometimes called the Wolverine blend.

Rationale: the two are studied through different mechanisms, gut and local tissue repair for BPC-157, broader cell-migration signaling for TB-500, and they're commonly discussed as complementary rather than redundant.

Protocol as run: both peptides on their own schedules from above, run over the same general weeks rather than on a single matched timetable.

Why it's paired: the two get marketed together constantly, largely because they answer to the same recovery-and-repair audience, not because there's a documented trial behind the combination.

Lighter stacks: GHK-Cu shows up alongside BPC-157 in skin and collagen-focused stacks, addressing repair from a different angle. This is rationale plus a loosely matched schedule, not a protocol with dedicated combination data.

Combinations to approach carefully: running BPC-157 alongside several other repair-focused peptides at once makes it harder to know which one is behind any change you notice, and we found no source addressing what a three- or four-peptide repair stack does as a combination rather than as separate parts.

Expected results timeline

Early days: this is mostly an adjustment period for the injection routine itself. Anything noticed in the first several days is more likely the routine or placebo than the compound doing its work.

During a course: this is where most of the self-reported changes cluster, digestive comfort, and subjective recovery from soft-tissue strain, none of it measured against a control group.

Cumulative, across repeated courses: this is the piece with the least real-world evidence behind it. The underlying data is overwhelmingly animal and cell work, not people, so a cumulative human effect is more assumption than finding.

What to expect realistically: a large, consistent animal evidence base and a genuinely small amount of human evidence. Mild, self-reported improvements in comfort or recovery are the most commonly described signal. A measurable change without some way of tracking it isn't a reasonable expectation.

Administration technique

1. The lyophilized powder is reconstituted with bacteriostatic water, at a concentration set by the reconstitution calculator for the target dose.
2. The solution is swirled gently to dissolve rather than shaken, since agitation can degrade the peptide.
3. The calculated volume is drawn into an insulin syringe.
4. A subcutaneous site is chosen, commonly the abdomen or near the area of concern, with sites rotated across the course.
5. The skin is pinched and the injection given at roughly a 45-degree angle, held for a few seconds before withdrawal.
6. Some schedules split the day's amount into two injections rather than one; no human study has directly compared the two, so which is preferable is genuinely unresolved rather than a settled preference.
7. Each injection is commonly logged by date, amount, and site, so a multi-week course doesn't rely on memory partway through.

Side effects and safety

Common: mild redness or irritation at the injection site.

Less common: mild digestive upset when taken orally on an empty stomach.

What we don't know: there's no completed large-scale human safety study for BPC-157 in tissue-repair or gut-comfort use specifically. Animal safety work has not identified a harmful dose, and the small human studies that exist reported no toxicity, but that's a narrower base than the amount of animal research would suggest.

Contraindications: pregnancy, breastfeeding, and use in minors all have no data behind them and should be avoided.

Drug interactions: none have been characterized. That's an absence of data, not evidence of safety.

BPC-157 vs. TB-500

If you're weighing BPC-157 against something else, TB-500 is the compound people actually cross-shop it against, since the two are marketed together constantly under the Wolverine name.

Choose BPC-157 if: gut comfort is part of what you're after, or you want the option of an oral form alongside an injected one.

Choose TB-500 if: you're focused on broader tissue repair and less concerned with a digestive angle.

Stacking the two: this is the single most common peptide combination in this space, run on separate schedules rather than one matched protocol. See the full BPC-157 vs. TB-500 comparison for a deeper side-by-side, and the TB-500 research notes for pricing and vendor info.

Storage and handling

Lyophilized powder: stable at room temperature or refrigerated, commonly described as good for 24 months or longer. Lot-specific stability should come from the vendor's certificate of analysis, not a general rule.

Reconstituted solution: refrigerate, and plan to use it within about 4 to 6 weeks.

The chronic-use injected pattern above, 200 to 300 mcg once daily for 4 to 12 weeks, can run longer than this window on its own. A course that stretches past 4 to 6 weeks means reconstituting a fresh vial partway through, not trying to make one reconstituted vial last the whole course.

Signs of degradation:

• Cloudiness or visible particles in a solution that was previously clear
• Discoloration of the powder or reconstituted liquid
• A course that produces none of the previously noticed subjective effects, though this is a soft signal at best

FAQ

Where does the 250 to 500 mcg figure actually come from? Not the one published human study, which used a much smaller oral amount. It sits between two different ways of scaling the animal dose up to a person, and it also divides neatly into a 5 milligram vial.

Once daily or twice daily? Sources disagree, and no human study has compared the two directly, so it's genuinely unresolved rather than a settled question.

Is oral the same as injected? No. Sources that address both treat them as separate protocols at different amounts, not the same dose taken a different way.

How long is a typical course? Most commonly 4 to 8 weeks, sometimes extended to 12 for chronic use.

Is it safe to combine with TB-500? No dedicated combination study exists. It's the most common pairing in this space, run on separate schedules rather than a single protocol.

Does body weight matter for dosing? The popular figures were written around a roughly 165 to 200 pound body and don't adjust for size, which is worth knowing if you're meaningfully lighter than that.

Is there human safety data? Limited. What exists reported no toxicity, but it's a much smaller base than the animal literature would suggest.

How is it stored? Room temperature or refrigerated as a powder, refrigerated and used within 4 to 6 weeks once reconstituted.

What's the difference between a 2 mg, 5 mg, and 10 mg vial? Only the concentration and how many vials your course total requires; the reconstitution calculator handles the arithmetic either way.

Bottom line

Key dosing takeaways:

• 250 to 500 mcg daily, subcutaneous, for 4 to 8 weeks, is the pattern most commonly referenced, though it traces to vendor education and a handful of named non-clinician sources rather than to the one published human study
• That human study used a dose roughly 600 times smaller, oral rather than injected, which is a large enough gap to know about before treating 250 mcg as settled
• Oral and injected are different protocols at different amounts, not the same dose by a different route

Best practices:

• Comparing vendors by course total in milligrams, not by vial count, is where the real price differences show up
• Logging each injection keeps a multi-week course from relying on memory
• A rest period between courses is standard across every version of this protocol, even though the specific ratio has no traceable source

Works best for people who:

• Want gut comfort and local tissue repair addressed together, with the option of an oral form
• Are comfortable running a widely used protocol whose popular number doesn't trace back to strong human evidence
• Are prepared to scale expectations to a mostly-animal evidence base rather than a mostly-human one